GlaxoSmithKline PLC Company Profile (NYSE:GSK)

About GlaxoSmithKline PLC

GlaxoSmithKline PLC logoGlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company's segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare. The Pharmaceuticals business develops and makes medicines to treat a range of acute and chronic diseases. The Vaccines business develops, produces and distributes over 1.9 million vaccines every day to people across the world. The Consumer Healthcare business develops and markets products in various categories, such as Wellness, Oral health, Nutrition and Skin health. The Pharmaceuticals Research and Development (R&D) focuses on the discovery and development in various areas of research, which include human immunodeficiency virus (HIV) and infectious diseases, oncology, immuno-inflammation, respiratory and rare diseases.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: N/A
  • Exchange: NYSE
  • Symbol: GSK
  • CUSIP:
Key Metrics:
  • Previous Close: $42.90
  • 50 Day Moving Average: $43.65
  • 200 Day Moving Average: $42.73
  • 52-Week Range: $37.82 - $45.58
  • Trailing P/E Ratio: 2681.25
  • Foreward P/E Ratio: 15.49
  • P/E Growth: 1.68
  • Market Cap: $104.27B
  • Outstanding Shares: 2,430,500,000
  • Beta: 0.85
Profitability:
  • Net Margins: 0.21%
  • Return on Equity: 56.57%
  • Return on Assets: 7.57%
Debt:
  • Debt-to-Equity Ratio: 3.57%
  • Current Ratio: 0.93%
  • Quick Ratio: 0.63%
Additional Links:
Companies Related to GlaxoSmithKline PLC:

Analyst Ratings

Consensus Ratings for GlaxoSmithKline PLC (NYSE:GSK) (?)
Ratings Breakdown: 2 Sell Ratings, 9 Hold Ratings, 10 Buy Ratings
Consensus Rating:Hold (Score: 2.38)
Consensus Price Target: $48.25 (12.47% upside)

Analysts' Ratings History for GlaxoSmithKline PLC (NYSE:GSK)
Show:
DateFirmActionRatingPrice TargetDetails
9/23/2016Citigroup Inc.Reiterated RatingBuyView Rating Details
9/23/2016Piper Jaffray Cos.Initiated CoverageOverweightView Rating Details
9/22/2016JPMorgan Chase & Co.Reiterated RatingNeutralView Rating Details
9/20/2016Bank of America Corp.Reiterated RatingBuy$50.00View Rating Details
9/16/2016Beaufort SecuritiesReiterated RatingBuyView Rating Details
9/14/2016Jefferies GroupReiterated RatingBuyView Rating Details
9/13/2016BNP ParibasDowngradeNeutral -> UnderperformView Rating Details
9/12/2016HSBCReiterated RatingBuyView Rating Details
8/17/2016Shore CapitalReiterated RatingHoldView Rating Details
8/12/2016ArgusBoost Price TargetBuy$48.00 -> $50.00View Rating Details
7/28/2016Goldman Sachs Group Inc.Reiterated RatingBuyView Rating Details
6/27/2016Deutsche Bank AGReiterated RatingHoldView Rating Details
5/26/2016Cowen and CompanyDowngradeOutperform -> Market PerformView Rating Details
5/5/2016Oddo SecuritiesUpgradeReduce -> BuyView Rating Details
2/26/2016Cantor FitzgeraldInitiated CoverageHoldView Rating Details
2/4/2016Sanford C. BernsteinBoost Price TargetMarket Perform$43.00 -> $45.00View Rating Details
1/27/2016Bryan, Garnier & CoUpgradeNeutral -> BuyView Rating Details
12/21/2015Leerink SwannReiterated RatingMarket Perform$48.00View Rating Details
11/6/2015Morgan StanleyReiterated RatingNeutralView Rating Details
10/31/2015Societe GeneraleReiterated RatingSellView Rating Details
10/20/2015Credit Suisse Group AGUpgradeUnderperform -> NeutralView Rating Details
6/26/2015Liberum CapitalUpgradeSell -> HoldView Rating Details
5/22/2015Berenberg BankReiterated RatingHoldView Rating Details
4/16/2015Barclays PLCReiterated RatingOverweightView Rating Details
3/30/2015Kepler Capital MarketsReiterated RatingHoldView Rating Details
2/6/2015Panmure GordonReiterated RatingHoldView Rating Details
2/5/2015S&P Equity ResearchDowngradeHoldView Rating Details
1/22/2015New Street ResearchDowngradeReduceView Rating Details
(Data available from 9/29/2014 forward)

Earnings

Earnings History for GlaxoSmithKline PLC (NYSE:GSK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/3/2016Q415$0.18$0.18$6.28 billion$6.29 billionViewN/AView Earnings Details
10/28/2015Q3$0.60$0.71$6.07 billion$6.13 billionViewN/AView Earnings Details
7/29/2015Q215$0.50$0.53ViewN/AView Earnings Details
5/6/2015Q115$0.55$0.48ViewN/AView Earnings Details
2/4/2015Q414$0.86$0.82$6.14 billion$6.19 billionViewN/AView Earnings Details
10/22/2014Q314$0.79$0.90ViewListenView Earnings Details
7/23/2014Q114$0.71$0.65ViewN/AView Earnings Details
4/30/2014Q413$0.72$0.70ViewN/AView Earnings Details
2/5/2014Q4$0.30$0.30$6.84 billion$6.91 billionViewN/AView Earnings Details
10/23/2013Q313$0.31$10.31 billion$10.09 billionViewN/AView Earnings Details
7/24/2013$0.26$0.26$6.62 billionViewN/AView Earnings Details
4/25/2012$0.29$0.27ViewN/AView Earnings Details
2/7/2012$0.30$0.28ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for GlaxoSmithKline PLC (NYSE:GSK)
Current Year EPS Consensus Estimate: $2.60 EPS
Next Year EPS Consensus Estimate: $2.77 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161$0.50$0.50$0.50
Q2 20162$0.54$0.55$0.55
Q3 20161$0.77$0.77$0.77
Q4 20161$0.65$0.65$0.65
(Data provided by Zacks Investment Research)

Dividends

Current Dividend Information for GlaxoSmithKline PLC (NYSE:GSK)
Annual Dividend:$1.98
Dividend Yield:4.62%
Dividend Growth:2.50% (3 Year Average)
Payout Ratio:6,600.00% (Based on Trailing 12 Months of Earnings)
76.15% (Based on Current Year Consensus EPS Estimate)
71.48% (Based on Next Year Consensus EPS Estimate)

Dividend History for GlaxoSmithKline PLC (NYSE:GSK)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/27/2016$0.498/10/20168/12/201610/13/2016
4/28/2016$0.555/11/20165/13/20167/14/2016
10/28/2015$0.5811/10/201511/13/20151/14/2016
5/7/2015quarterly$0.585.22%5/13/20155/15/20157/9/2015
2/5/2015quarterly$0.706.05%2/18/20152/20/20154/9/2015
10/23/2014quarterly$0.615.41%11/5/201411/7/20141/8/2015
7/24/2014quarterly$0.655.18%8/6/20148/8/201410/2/2014
5/1/2014quarterly$0.644.62%5/14/20145/16/20147/10/2014
2/5/2014$0.752/19/20142/21/20144/10/2014
2/6/2014quarterly$0.755.73%2/19/20142/21/20144/10/2014
10/24/2013quarterly$0.624.76%11/13/201311/15/20131/9/2014
7/25/2013quarterly$0.554.27%8/7/20138/9/201310/3/2013
4/25/2013quarterly$0.554.25%5/8/20135/10/20137/11/2013
2/7/2013quarterly$0.070.61%2/20/20132/22/20134/11/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for GlaxoSmithKline PLC (NYSE:GSK)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for GlaxoSmithKline PLC (NYSE:GSK)
DateHeadline
News IconGlaxoSmithKline plc appoints Brian McNamara as CEO of GSK Consumer Healthcare (NYSE:GSK)
www.pressreleasepoint.com - September 29 at 5:13 PM
fool.com logoThe Highest-Yielding Drug Stocks (NYSE:GSK)
www.fool.com - September 29 at 5:13 PM
reuters.com logoBRIEF-GlaxoSmithKline appoints new consumer healthcare CEO (NYSE:GSK)
www.reuters.com - September 29 at 10:23 AM
4-traders.com logoGlaxoSmithKline : Glaxo Appoints McNamara To Succeed Walmsley In Consumer Healthcare (NYSE:GSK)
www.4-traders.com - September 29 at 10:23 AM
News IconGlaxoSmithKline Appoints New Consumer Healthcare Chief (NYSE:GSK)
ih.advfn.com - September 29 at 10:23 AM
marketexclusive.com logoGlaxoSmithKline Plc (NYSE:GSK), Oncodesign Sign Deal For Francois Hyafil Research Center Acquisition (NYSE:GSK)
marketexclusive.com - September 29 at 10:23 AM
uk.finance.yahoo.com logoAfter CEO move, GSK picks ex-Novartis exec to head consumer unit (NYSE:GSK)
uk.finance.yahoo.com - September 29 at 10:23 AM
sg.finance.yahoo.com logoAfter CEO move, GSK picks ex-Novartis executive to head consumer unit (NYSE:GSK)
sg.finance.yahoo.com - September 29 at 10:23 AM
bloomberg.com logoGlaxo Appoints Brian McNamara Chief of Consumer Health Division (NYSE:GSK)
www.bloomberg.com - September 29 at 10:23 AM
thestreet.com logoGlaxoSmithKline (GSK) Stock Down, McNamara Named CEO of Consumer Healthcare Unit (NYSE:GSK)
www.thestreet.com - September 29 at 10:22 AM
publicnow.com logoGlaxoSmithKline announces intention to sell remaining holding in Aspen (NYSE:GSK)
www.publicnow.com - September 29 at 10:22 AM
publicnow.com logoGlaxoSmithKline completes sale of remaining Aspen shares (NYSE:GSK)
www.publicnow.com - September 29 at 10:22 AM
marketwatch.com logoGlaxoSmithKline to sell remaining stake in Aspen (NYSE:GSK)
www.marketwatch.com - September 28 at 5:08 PM
News IconIs GlaxoSmithKline plc (NYSE:GSK), a large market cap stock a smart buy? (NYSE:GSK)
twincountynews.com - September 28 at 5:08 PM
finance.yahoo.com logoAriel Funds Comments on GlaxoSmithKline plc (NYSE:GSK)
finance.yahoo.com - September 28 at 5:08 PM
News IconGlaxoSmithKline plc (ADR) (GSK) Steps ahead in Lupus Treatment - Smаrt Stоck Nеws (NYSE:GSK)
www.smartstocknews.com - September 28 at 10:11 AM
thestreet.com logoGlaxoSmithKline Vaccines for Malaria, Zika Make It a Likely Winner (NYSE:GSK)
www.thestreet.com - September 28 at 10:11 AM
marketrealist.com logoTeva Is Well Placed to Dominate the European Generics Market (NYSE:GSK)
marketrealist.com - September 28 at 10:11 AM
prnewswire.com logoFighting Addiction and Other Unmet Medical Needs with Cannabidiol (NYSE:GSK)
www.prnewswire.com - September 27 at 9:56 AM
News IconTop Gainers of the Day: GlaxoSmithKline plc (NYSE:GSK) from Drug Manufacturers – Major (NYSE:GSK)
twincountynews.com - September 27 at 9:56 AM
News IconVigorous Stocks Need to Consider: GlaxoSmithKline plc (NYSE:GSK), Encana Corporation (NYSE:ECA), L Brands, Inc ... - Street Wise Report (press release) (blog) (NYSE:GSK)
streetwisereport.com - September 26 at 5:28 PM
finance.yahoo.com logoGlaxo/J&J File BLA for Rheumatoid Arthritis Drug in the U.S. (NYSE:GSK)
finance.yahoo.com - September 26 at 9:59 AM
News IconGSK Submits for Subcutaneous Formulation of Benlysta in US, Europe (NYSE:GSK)
ih.advfn.com - September 23 at 10:18 AM
nasdaq.com logoGSK Announces U.S. Regulatory Submission For Sirukumab In Rheumatoid Arthritis (NYSE:GSK)
www.nasdaq.com - September 23 at 10:18 AM
4-traders.com logoGlaxoSmithKline : Files US Regulatory Application for Sirukumab in Rheumatoid Arthritis (NYSE:GSK)
www.4-traders.com - September 23 at 10:18 AM
ft.com logo[$$] GSK's 'fiercely competitive' Emma Walmsley faces test of experience (NYSE:GSK)
www.ft.com - September 23 at 10:18 AM
publicnow.com logoUS Regulatory Submission for sirukumab in RA (NYSE:GSK)
www.publicnow.com - September 23 at 10:18 AM
publicnow.com logoGSK announces US regulatory submission for sirukumab in rheumatoid arthritis (NYSE:GSK)
www.publicnow.com - September 23 at 10:18 AM
News IconAlphaValue Reaffirms “Buy” Rating for GlaxoSmithKline plc (GSK) - Petro Global News 24 (NYSE:GSK)
petroglobalnews24.com - September 22 at 5:23 PM
proactiveinvestors.co.uk logo52-week High/Low: - Proactive Investors UK (NYSE:GSK)
www.proactiveinvestors.co.uk - September 21 at 3:32 PM
News IconTrending Stock - GlaxoSmithKline plc's (GSK) - Hot Stocks Point (NYSE:GSK)
www.hotstockspoint.com - September 21 at 3:32 PM
insidermonkey.com logoMedecins Sans Frontieres Happy with GlaxoSmithKline PLC (ADR) (GSK) Price Reduction For Synflorix - Insider Monkey (blog) (NYSE:GSK)
www.insidermonkey.com - September 21 at 3:32 PM
News IconMedecins Sans Frontieres Happy with GlaxoSmithKline PLC (ADR) (GSK) Price Reduction For Synflorix (NYSE:GSK)
feedproxy.google.com - September 20 at 3:55 PM
marketexclusive.com logoMedecins Sans Frontieres Happy with GlaxoSmithKline plc (ADR) (NYSE:GSK) Price Reduction For Synflorix - Market Exclusive (NYSE:GSK)
marketexclusive.com - September 20 at 10:26 AM
bloomberg.com logoGlaxo Names Consumer Head Emma Walmsley to Succeed Witty as CEO - Bloomberg (NYSE:GSK)
www.bloomberg.com - September 20 at 10:26 AM
News IconHigh Market Cap Stock of the Day – GlaxoSmithKline plc (NYSE:GSK) (NYSE:GSK)
twincountynews.com - September 19 at 5:24 PM
News IconHC Stocks in Drift! GlaxoSmithKline plc (ADR) (GSK), Acadia Healthcare Company Inc (NASDAQ:ACHC) - share market updates (press release) (NYSE:GSK)
sharemarketupdates.com - September 19 at 9:54 AM
sg.finance.yahoo.com logoGSK cuts vaccine price for refugees, bowing to pressure (NYSE:GSK)
sg.finance.yahoo.com - September 19 at 9:54 AM
News IconGSK appoints Raj Khemani as IT lead (NYSE:GSK)
www.infotechlead.com - September 18 at 9:49 AM
investors.com logoDrugmakers Must Report Clinical Trial Results Once Kept Secret (NYSE:GSK)
www.investors.com - September 16 at 5:11 PM
sg.finance.yahoo.com logoGSK closes UK factory due to flooding (NYSE:GSK)
sg.finance.yahoo.com - September 16 at 9:10 AM
marketrealist.com logoRoche’s Oncology Wheelhouse Stacked with Competitive Drugs (NYSE:GSK)
marketrealist.com - September 16 at 9:10 AM
finance.yahoo.com logoGlaxo (GSK) Publishes Phase III Data on Shingles Vaccine (NYSE:GSK)
finance.yahoo.com - September 15 at 5:40 PM
marketrealist.com logoSanofi’s Chase for Zika Virus Vaccine Could Drive Its Share Price (NYSE:GSK)
marketrealist.com - September 15 at 5:40 PM
thestreet.com logo4 Foreign Stocks to Fire Up Your Portfolio (NYSE:GSK)
www.thestreet.com - September 15 at 5:40 PM
thestreet.com logoBullish on SoftBank, ASML, Royal Dutch Shell and GlaxoSmithKline (NYSE:GSK)
www.thestreet.com - September 15 at 5:40 PM
News IconMEDICAL & HEALTHCARE JOB | Recruitment Lead at GlaxoSmithKline (GSK) (NYSE:GSK)
bizwatchnigeria.ng - September 15 at 8:24 AM
proactiveinvestors.co.uk logoGlaxoSmithKline's shingles vaccine lasts four years in elderly patients (NYSE:GSK)
www.proactiveinvestors.co.uk - September 15 at 8:24 AM
4-traders.com logoGlaxoSmithKline : GSK announces EU regulatory submission for sirukumab in rheumatoid arthritis | GSK (NYSE:GSK)
www.4-traders.com - September 15 at 8:24 AM
streetinsider.com logoForm 6-K GLAXOSMITHKLINE PLC For: Sep 15 (NYSE:GSK)
www.streetinsider.com - September 15 at 8:24 AM

Social

GlaxoSmithKline PLC (NYSE:GSK) Chart for Thursday, September, 29, 2016


Last Updated on 9/29/2016 by MarketBeat.com Staff